| Home Market Dynamics You and Market Sector Analysis Company Insights AI Investing About Contact Us Login |
| The price action of Health Care (XLV) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The overall sentiment for Health Care sector is very positive (overall 2, positive 2.9, negative -1) on 20251014. The forces of Sentiment towards Fundamentals (2.3), Price Level (2), Option Speculation (1.5), and Broad Market Trend (-0.2) will drive up the price. The forces of Sector Price Trend (-0.7), Valuation Sentiment (-1), and Market Risk Prefrence (0) will drive down the price. 'Buy the dips' is the preferred trading strategy. Hourly SMA 20 trend line is likely to provide a support from any pullbacks. The swing to upside will be significant considering the high positive sentiment forces (2.9). The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on XLV trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. |
| Date | Attention | Average Attention | Price | Price Level | Change | SMA10 Trend | Market Sentiment | Trend Sentiment | Fundamentals | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-14 | 2% | 0.9% | 142.33 | 66 | 0.27% | 0.21% | 0.7 | -0.4 | 2.3 | 5.8 |
| 2025-10-13 | 0% | 0.9% | 141.94 | 65 | -0.13% | 0.42% | 0.5 | -0.3 | 2.1 | 4 |
| 2025-10-12 | 1% | 1% | 1.5 | 0.4 | 2.4 | -4 | ||||
| 2025-10-11 | 1% | 0.9% | 1.4 | 0.4 | 2.3 | 5 | ||||
| 2025-10-10 | 1% | 0.9% | 142.12 | 67 | -1.46% | 0.49% | 1.5 | 0.4 | 2.4 | 1.6 |
| 2025-10-09 | 0% | 1% | 144.23 | 84 | -0.17% | 0.71% | 2.1 | 1 | 2.4 | 8 |
| 2025-10-08 | 1% | 1.3% | 144.48 | 89 | 0.17% | 0.57% | 2.2 | 0.9 | 2.4 | 5 |
| 2025-10-07 | 2% | 1.4% | 144.24 | 92 | 0.1% | 0.5% | 2.1 | 1.2 | 2.2 | 2.4 |
| 2025-10-06 | 1% | 1.4% | 144.1 | 97 | -0.48% | 0.58% | 2.6 | 1.7 | 2.5 | 6 |
| 2025-10-05 | 0% | 1.4% | 2.2 | 1.8 | 2 | 0 | ||||
| Both emotion scores and sentiment scores are calculated in a -10 - +10 scale. | The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| 1 (8) Medline Net Sales in First Half Reach $13.5 Billion Ahead of IPO Medline is telling prospective investors in its initial public offering that it had about $13.5 billion in net sales in the first half of 2025, an increase of roughly 9.7% from last year, according to people familiar with the matter. (https://www.bloomberg.com/) Tue. Oct 14, 2025 | |
| 2 (7) Higher education CEO on AI's growing role in health-care degree market Adtalem CEO Steve Beard is leading the health-care education company through an AI transformation, one he believes will further complement what it already does. (https://www.cnbc.com/) Tue. Oct 14, 2025 | |
| 3 (-7) Humana Loses Court Battle Over Medicare Advantage Ratings, Billions In Payments At Risk Texas court rules against Humana, upholding Medicare Advantage bonus cuts and risking billions in insurer revenue tied to star ratings. (https://www.benzinga.com/) Tue. Oct 14, 2025 | |
| 4 (7) HealthEquity CEO talks new GLP-1 & HSA enrollment programs HealthEquity (HQY) president and CEO, Scott Cutler, joins Market Catalysts to discuss the company's new GLP-1 program and direct Health Savings Account (HSA) enrollment. Cutler also outlines the company's new features and their role amid healthcare affordability challenges. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts. (https://finance.yahoo.com/) Tue. Oct 14, 2025 | |
| 5 (5) Intuitive Surgical: Why Congress Is Buying Ahead of Earnings Market Analysis by covering: Intuitive Surgical Inc. Read 's Market Analysis on Investing.com (https://www.investing.com/) Tue. Oct 14, 2025 | |
| 6 (6) J&J to spin off orthopedics business, sees 2026 sales growth of over 5% J&J to spin off orthopedics business, sees 2026 sales growth of over 5% (https://www.investing.com/) Tue. Oct 14, 2025 | |
| 7 (5) Johnson & Johnson outlook, Oracle & AMD team up, GM's EV charge Morning Brief host Julie Hyman outlines three of Wall Street's top stories on Tuesday: Johnson & Johnson (JNJ) earnings, the Oracle (ORCL) and AMD (AMD) chip deal, and General Motors' (GM) electric vehicle (EV) charge. To watch more expert insights and analysis on the latest market action, check out more Morning Brief. (https://finance.yahoo.com/) Tue. Oct 14, 2025 | |
| 8 (8) 3 things Oura will invest in after $900M funding round: Oura CEO Oura, a health tech company that makes fitness tracker rings, is valued at nearly $11 billion after raising $900 million in its latest funding round. Oura CEO Tom Hale joins Morning Brief with Julie Hyman to discuss three things the company will use the funding to invest in: artificial intelligence (AI), expanding its international business, and continuing to integrate into the traditional healthcare system. To watch more expert insights and analysis on the latest market action, check out more Morning Brief. (https://finance.yahoo.com/) Tue. Oct 14, 2025 | |
| 9 (7) J&J to spin off orthopedics business, sees 2026 sales growth of over 5% (Reuters) -Johnson & Johnson said on Tuesday it plans to separate its orthopedics business into a standalone company named DePuy Synthes within the next 18 to 24 months, marking its second major spinoff in two years as it sharpens focus on higher-growth healthcare segments. J&J; also outlined expectations for faster growth into 2026, driven by new drug launches and a strengthened medical devices portfolio, and raised its 2025 sales forecast after reporting quarterly earnings that topped Wall St (https://finance.yahoo.com/) Tue. Oct 14, 2025 | |
| 10 (8) Johnson & Johnson’s stock heads for a record after a profit beat and plans for another spinoff Johnson & Johnson’s stock rose toward a record after a beat-and-raise earnings report and announcement of plans to separate its orthopedics business. (https://www.marketwatch.com/) Tue. Oct 14, 2025 | |
| 11 (8) Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthopedics business, DePuy Synthes. (https://www.benzinga.com/) Tue. Oct 14, 2025 | |
| 12 (8) Johnson & Johnson’s stock heads for a record after a profit beat and plans for another spinoff Johnson & Johnson’s stock rose toward a record after a beat-and-raise earnings report and announcement of plans to separate its orthopedics business. (https://www.marketwatch.com/) Tue. Oct 14, 2025 | |
| 13 (4) Where Will Pfizer Be in 5 Years? Pfizer is working hard to deal with some big headwinds it has coming up, but in five years, this should all be in the past. (https://www.fool.com/) Mon. Oct 13, 2025 | |
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA